Atypical Femoral Fractures in Patients Taking Longterm Alendronate

Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate.

n engl j med 358;12 www.nejm.org march 20, 2008 1304 approved indications in postmenopausal and male osteoporosis, we recommended that teriparatide be considered for patients at high risk for fracture who require sustained use of glucocorticoids and who have either osteoporosis or low bone mass with a prevalent fracture. In his editorial, Sambrook suggests the use of teriparatide as a firstline...

Simultaneous bilateral atypical femoral fractures after alendronate therapy.

Do atypical femoral fractures in patients with prolonged alendronate treatment heal?

Osteoporosis, which is a major health problem, may have an adverse impact on the economic status of the society and the quality of the life of the patients. Long-term alendronate use may cause an increased susceptibility to fractures with an increased risk of delayed union. In this article, we describe two patients on long-term alendronate therapy which were treated for atypical femoral fractur...

Atypical femoral fractures mimicking metastatic lesions in 2 patients taking denosumab

© 2017 The Author(s). Published by Taylor & Francis on behalf of the Nordic Orthopedic Federation. This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (https://creativecommons.org/licenses/by-nc/3.0) DOI 10.1080/17453674.2016.1277412 Patient 1 A 75-year-old woman with a history of metastatic breast and non-small-cell lung cancer ...

Atypical femoral fractures.

Bisphosphonates (BPs) represent the most widely used therapy for osteoporosis. Recently, a relationship between long-term treatment with BPs and a subset of atypical femoral fractures (AFFs) from below the lesser trochanter to the sovracondilar line has been described. Many etiopathogenetic theories have been invoked to explain AFFs: reduced bone turnover and increased osteoblast bone appositio...